Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the November 26, 2012 deadline to move for appointment as lead plaintiff in the securities class litigation against Questcor Pharmaceuticals, Inc. (“Questcor” or the “Company”) (NASDAQ: QCOR), brought on behalf of all persons who purchased or otherwise acquired the securities of Questcor between April 4, 2011 and September 21, 2012, inclusive (the “Class Period”).
If you purchased or otherwise acquired Questcor securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 26, 2012. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
Questcor shareholders who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon Lee of Lieff Cabraser toll-free at 1 (800) 541-7358.
The complaints charge Questcor and certain of its senior executives with violations of the Securities Exchange Act of 1934. Questcor is a California-based biopharmaceutical company. The Company’s primary product is H.P. Acthar Gel (“Acthar”), an injectable drug approved by the U. S. Food and Drug Administration (“FDA”) for the treatment of 19 conditions, including multiple scelorosis (“MS”), nephrotic syndrome and infantile spasms.On September 19, 2012, Citron Research reported that Aetna Inc. (“Aetna”), one of the nation’s largest insurance companies, had revised its policy regarding Acthar, extensively limiting coverage for the drug. Aetna had engaged in a review of the 19 indications for which the FDA had approved Acthar and determined that clinical research suggested the drug is only “medically necessary” for West syndrome, a rare condition that causes infantile spasms, and not for other indications, such as MS. On this news, the price of Questcor’s common stock fell $24.17 per share to close at $26.35 per share on September 19, 2012, a one-day decline of nearly 48%.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV